Effectiveness of topical infliximab in a mouse model of experimental dry eye

Cornea

Volumn 31, Issue 11 SUPPL.1, 2012, Pages

  Li, Zhengri ^a   Choi, Won ^a   Oh, Han Jin ^a   Yoon, Kyung Chul ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

experimental dry eye; infliximab; ophthalmic solutions; tumor necrosis factor

Indexed keywords

BALANCED SALT SOLUTION; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONJUNCTIVA; CONTROLLED STUDY; CORNEA; DRUG EFFICACY; DRY EYE; EXPERIMENTAL DRY EYE; EXPERIMENTAL MODEL; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CELL COUNT; CONJUNCTIVA; DISEASE MODELS, ANIMAL; DRY EYE SYNDROMES; FEMALE; FLOW CYTOMETRY; GOBLET CELLS; IMMUNOENZYME TECHNIQUES; INTERFERON-GAMMA; INTERLEUKINS; MICE; MICE, INBRED C57BL; OPHTHALMIC SOLUTIONS; TEARS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867363821     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31826a80ea     Document Type: Conference Paper

References (41)

1. Lemp MA, Baudouin C, Baum J, et al. The definition of classification of dry eye diseases: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5: 75-92.
2. Stern ME, Pflugfelder SC. Inflammation in dry eye. Ocul Surf. 2004;2: 124-130.
3. Pflugfelder SC, de Paiva CS, Li DQ, et al. Epithelial-immune cell interaction in dry eye. Cornea. 2008;27(suppl 1):S9-S11.
4. Pflugfelder SC, Stern ME; Symposium participants. Immunoregulation on the ocular surface: 2nd Cullen Symposium. Ocul Surf. 2009;7: 67-77.
5. Yoon KC, De Paiva CS, Qi H, et al. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. Invest Ophthalmol Vis Sci. 2007;48:2561-2569.
6. Yoon KC, Park CS, You IC, et al. Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest Ophthalmol Vis Sci. 2010;51:643-650.
7. De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009;2:243-253.
8. Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999;19:201-211.
9. Yoon KC, Jeong IY, Park YG, et al. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea. 2007;26:431-437.
10. Massingale ML, Li X, Vallabhajosyula M, et al. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea. 2009;28:1023-1027.
11. Lam H, Bleiden L, de Paiva CS, et al. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol. 2009;147:198-205.
12. Klareskog L, van der Heijde D, de Pager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomized controlled trial. Lancet. 2004;363:675-681.
13. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-1411.
14. St Clair EW, van der Heijde M, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum. 2004;50:3432-3443.
15. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903-912.
16. Murphy CC, Greiner K, Plskova J, et al. Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. Arch Ophthalmol. 2004;122:845-851.
17. Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352-356.
18. Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003;110:1449-1453.
19. Odorcic S, Keystone EC, Ma JJ. Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up. Cornea. 2009;28:89-92.
20. Zhu Z, Stevenson D, Schechter JE, et al. Tumor necrosis factor inhibitor gene expression suppresses lacrimal gland immunopathology in a rabbit model of autoimmune dacryoadenitis. Cornea. 2003;22:343-351.
21. Steinfeld SD, Demols P, Salmon I, et al. Infliximab in patients with primary Sjögren's syndrome: A pilot study. Arthritis Rheum. 2001;44:2371-2375.
22. Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjögren's syndrome: one-year followup. Arthritis Rheum. 2002;46:3301-3303.
23. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren's syndrome: Results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270-1276.
24. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjögren's syndrome: A twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240-2245.
25. Zandbelt MM, de Wilde P, van Damme P, et al. Etanercept in the treatment of patients with primary Sjögren's syndrome: A pilot study. J Rheumatol. 2004;31:96-101.
26. Moutsopoulos NM, Katsifis GE, Angelov N, et al. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. Ann Rheum Dis. 2008;67:1437-1443.
27. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83:526-535.
28. De Paiva CS, Villarreal AL, Corrales RM, et al. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferongamma. Invest Ophthalmol Vis Sci. 2007;48:2552-2560.
29. Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T cell-mediated Sjögren's syndrome-like lacrimal keratoconjunctivitis. J Immunol. 2006;176:3950-3957.
30. Yoon KC, De Paiva CS, Qi H, et al. Desiccating environmental stress exacerbates autoimmune lacrimal keratoconjunctivitis in non-obese diabetic mice. J Autoimmun. 2008;30:212-221.
31. Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens. 2006;32:272-276.
32. De Paiva CS, Corrales RM, Villarreal AL, et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vis Sci. 2006;47:2847-2856.
33. Taylor PC, Feldmann M. Anti-TNF biologic agents: Still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5:578-582.
34. Notley CA, Inglis JJ, Alzabin S, et al. Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells. J Exp Med. 2008;205:2491-2497.
35. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature. 2007;445:866-873.
36. Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol. 2010;3:239-258.
37. Bosè F, Raeli L, Garutti C, et al. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues. Clin Immunol. 2011;139:164-176.
38. Vosters JL, Yin H, Roescher N, et al. Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome. Arthritis Res Ther. 2009; 11:R189.
39. Yoon KC, Ahn KY, Choi W, et al. Tear production and ocular surface changes in experimental dry eye after elimination of desiccating stress. Invest Ophthalmol Vis Sci. 2011;52:7267-7273.
40. Erickson SL, de Sauvage FJ, Kikly K, et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature. 1994;372:560-563.
41. Chan KF, Siegel MR, Lenardo JM. Signaling by the TNF receptor superfamily and T cell homeostasis. Immunity. 2000;13:419-422.